Clinical Trial Update: Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pinometostat and azacitidine in patients with 11q23/MLL rearranged AML across relapsed, refractory, or newly diagnosed settings; comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Mllt3-mll
• Leukemia Cutis

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pinometostat (pinometostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-09